Lumos Pharma, Inc.
https://lumos-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumos Pharma, Inc.
Rare Pediatric Disease Voucher Program Gains Temporary Extension From House Committee
US incentive program would gain only four more years, despite calls for a permanent extension.
Rare Pediatric Priority Review Voucher Program Seems Headed For Short-Term Renewal
Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.
Merck Warned Of Q2 Slump, But How Far Did Revenue Fall?
The company previously cut 2020 revenue expectations by $2.5bn, including $1.7bn for pharma products. Keytruda’s dominance and portfolio diversification also may dominate second quarter call.
Merck & Co's Gerberding Adds Dose Of Reality To COVID-19 Debate
The US giant's chief patient officer and former head of the CDC, is proud of the "incredible collaboration" going on across the biopharmaceutical industry to tackle coronavirus but says "we have to be honest that we really don't understand this disease."
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- BioProtection Systems Corporation (BPS)
- BlueLink Pharmaceuticals
- NewLink Genetics
- NewLink Genetics Corporation